$ELAN

Elanco Animal Health Inc

Elanco develops and sells animal health products and services to help prevent and treat disease in pets and farm animals. Its customers include farmers, pet owners, veterinarians, distributors, retailers and animal producers. Elanco operates as a single segment and sells products under approximately 200 brands in more than 90 countries. It is headquartered in Indianapolis, Indiana. Its pet health portfolio includes parasiticides, dermatology treatments, vaccines and pain therapies, including the Advantage, Credelio and Tru families, Seresto, Zenrelia and Galliprant. Farm animal products for cattle, poultry, swine and sheep include medicated feed additives, antibiotics, vaccines, insecticides and enzymes, such as Rumensin, Experior, Maxiban and Monteban. Elanco sells pet products mainly through third-party distributors and retailers and directly to veterinarians; farm animal products are sold through distributors and directly to producers.

0
0
1

No SEC Form 4 filings for $ELAN in the last 30 days.

See all $ELAN insider activity →
Low

Lame, suffocated and dead: The drug supersizing America’s cattle

Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, has faced scrutiny due to reported health issues. Studies linked it to lameness, bloat, and deaths, though the FDA attributed these to other factors. Despite concerns, Experior generated over $200M in 2025 sales, with over half of U.S. feedlot cattle receiving it. The FDA and Elanco defend its safety and efficacy.

KeyBanc reiterates Elanco Animal Health stock rating on strong Q3

KeyBanc maintained an Overweight rating and $30.00 price target for Elanco Animal Health (NYSE:ELAN), citing strong Q3 results and confidence in 2027 outlook. Gross margin expanded to 56.1% YoY. Elanco reported Q3 adjusted earnings of $0.27 per share, beating estimates, and raised its full-year outlook. Analysts expect mid-single-digit organic revenue growth and further gross margin expansion.

ELAN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning ELAN (Elanco Animal Health Inc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent ELAN coverage spans financial news, earnings and regulation.

What's driving ELAN

AlphAI scores every news story that mentions ELAN with an AI model for sentiment and relevance, and aggregates insider trades from Elanco Animal Health Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ELAN

Score

Lame, suffocated and dead: The drug supersizing America’s cattle

Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, has faced scrutiny due to reported health issues. Studies linked it to lameness, bloat, and deaths, though the FDA attributed these to other factors. Despite concerns, Experior generated over $200M in 2025 sales, with over half of U.S. feedlot cattle receiving it. The FDA and Elanco defend its safety and efficacy.

$ELANHighAI 8/10

KeyBanc reiterates Elanco Animal Health stock rating on strong Q3

KeyBanc maintained an Overweight rating and $30.00 price target for Elanco Animal Health (NYSE:ELAN), citing strong Q3 results and confidence in 2027 outlook. Gross margin expanded to 56.1% YoY. Elanco reported Q3 adjusted earnings of $0.27 per share, beating estimates, and raised its full-year outlook. Analysts expect mid-single-digit organic revenue growth and further gross margin expansion.

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More

Wall Street analysts released research calls on various companies. Upgrades include Akamai (AKAM) to Strong Buy, BlackRock (BLK) to Buy, and Venture Global (VG) to Overweight. Downgrades include Apple (AAPL) to Hold, Elanco (ELAN) to Hold, and Zoetis (ZTS) to Hold. Initiations include Ford (F) with Overweight and Sunoco (SUN) with Overweight. Markets were mixed, with Nasdaq futures lower and Treasury yields higher.

Related tickers